Patient enrolment completed for fruquintinib’s Phase II study in non-small cell lung cancer
This randomised, double-blind, placebo-controlled, multi-centre, POC Phase II study is targeted at treating non-squamous NSCLC patients who have failed second-line standard chemotherapy. A total of 91 patients have now been randomised to receive fruquintinib plus best supportive care or placebo plus BSC at a 2:1 ratio. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety. As a result of the rapid patient enrolment, data from this trial is expected in mid of 2015.
Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.